Pinned Tweet
Replying to @goldencaskcap @brendan_49
I think large pharmas would be wise to dig through the early stage pipeline of some Chinese biotechs right now. They are struggling and selling their drugs in China would never be commercially viable. For every new target (CD24 etc) there prob is a Chinese bio doing it
He knows how to pick the winners!
In Depth: Alice Huang, now famous for a dalliance with ex-Nvidia CEO Jensen Huang, turned a computing business with less than $100 in assets into a multibillion-dollar company in three years, all while developing a network of data centers across China. caixinglobal.com/2026-11-13/…
1
6
1,030
If ppl weren't such paranoid assholes, maybe those Chinese scientists would've stayed in the U.S. instead of building biotech companies back in China 🙄
Seriously when has any measure to contain or restrict Chinese technical development not resulted in expedited advances? 🐦🧠
Replying to @goldencaskcap
When China has its real sputnik moment, aided by talents that were pushed out by racism and paranoia elsewhere, I hope all those "China watchers" who fanned the rhetoric while sitting unaffected in their pretty chairs, can look in the mirror and say "JOB WELL DONE!".
LFC retweeted
A point I've been arguing for years but especially since my father died of metastatic cancer last year. The problem with treating life sciences like chips is that it gets crosswise with the very human dimension of medical innovation. China accounts for roughly 24% of cancer cases globally and around 30% of cancer-related deaths in the world - and when cancer is such a scourge on a country that is making robust investments in the life sciences and biotech, it is inconceivable that said country will NOT eventually generate some drugs and therapeutics. Chinese biotechs stopped being just CROs doing contract outsourcing some time ago. And China's 2017 regulatory reform, including to clinical trials, has had a significant effect on clinical development prospects there.
Because the United States and other major economies have significant trade relationships with China, buying, selling, and investing are the focus of most conversations about how to balance cooperation with competition. But China is now a significant player in the advance of knowledge, capacity, and innovation in areas that touch the public interest. This is certainly going to include, for example, cancer and other disease research but also next generation energy solutions and more. When I published my book, "China's Techno-Warriors" in 2003, much less wrote it as a Stanford PhD dissertation in the 1990s, the push and pull between technonationalism and technoglobalism didn't have the same salience because China wasn't nearly as innovative in areas like life sciences and pharma. But if it is now no longer accurate to just say, "we innovate, China copycats" as if THAT is the end of the story, or “we are at the frontier, Chinese tech is only at the low end,” then we need a robust conversation about what is to be gained or lost from cooperation or non-cooperation with China, and how to balance this with the very real security threats that emanate from Beijing.
This is personal for me because my dad died. Would I have loved to save him with a cancer treatment from anywhere, even China? Emphatically and obviously yes. But the conversation in this country about Chinese innovation, prospects and potential human benefits from co-innovation, and how to wrestle with both Chinese technonationalism and our own very real technonationalism doesn't seem healthy at all right now. We have universities, laboratories, and companies that want to tap the Chinese innovation engine, on the one hand, and security professionals, on the other, who note that China is a strategic rival and, in some areas, a national security threat.
It seems to me we need a more serious debate about whether and what cooperation is or isn’t in the public and human interest, and how to balance the advance of knowledge with national security and competitiveness imperatives. The current trend across the West is to attenuate and restrict all such partnerships with China. But in the life sciences, for instance, we should surely be asking "what is the public interest?" now that China is developing drugs and therapeutics that can cure diseases and treat our ailing family members. It was too late for my dad but maybe not for someone else's dad down the road.
We need some common-sense parameters as the entire issue of collaboration with China becomes more fraught. Life sciences strikes me as a most logical place to do that.
Read this first sentence twice. And then read the whole piece.
“Someone whose life is saved by a new medicine is unlikely to care whether it was invented at home or on the other side of the world.” economist.com/leaders/2026/0…
Trade here is basically this gets him fired like ICE Barbie. Place your bets 😉
Some context for the UniQure $QURE post below:
Earlier today, the FDA held a media call with the same "senior FDA official" who spoke to me (and other reporters) individually earlier in the week.
The call was set up obstensibly so that this senior FDA official could rail against UniQure without going on the record. He did exactly this for 30 minutes, repeating the same criticisms, claiming Uniqure's Huntington’s therapy is a failure, the sham surgery would be blinded even if just small "nicks" in the skin were made in a 30-minute procedure, dismissing the idea of formally reviewing the therapy, disregarding outside scientific experts, and then accusing the media of not adequately covering what the FDA (and this official) have been doing.
Reporters from Bloomberg, STAT, NY Times, WSJ, Politico and other media organizations were on the call.
1
10
1,801
Do the right thing, guys xitter.cf/RepAuchincloss/status/…
This 'senior official' was Vinay Prasad. Disclosing trade secret information without legal authorization is a prohibited act under the FDCA & a criminal violation under the Trade Secrets Act.
4
901
Haven’t we learned enough from this? Honestly any AI can write a better report than that lol
4
1,640
The Patron Saint of XBI 🤣
NEW:
In another egregious personnel decision under the Trump administration, it is now being reported that longtime progressive Marxist Vinay Prasad who referred to President Trump’s supporters as criminals and compared them to drug addicts after saying he stabbed a Trump voodoo doll to “curse Trump” is apparently back at FDA after @MartyMakary advocated for him.
In the coming weeks, I will be ramping up my exposes of officials within HHS and FDA so the American people can see more of the pay for play rot themselves and how rabid Trump haters continue to be hired in the Trump administration.
There are several Senate Confirmation hearings coming up and I have multiple oppo books ready for distribution!
Should be a good time.
1
9
2,860
NMPA would have approved $repl haha
In all seriousness, if FDA is going to streamline clinical trials to compete against China, Vinay Prasad would not be the right person to develop the new framework.
6
1,714
Hahaha well done guys, well done!
Replying to @goldencaskcap
When China has its real sputnik moment, aided by talents that were pushed out by racism and paranoia elsewhere, I hope all those "China watchers" who fanned the rhetoric while sitting unaffected in their pretty chairs, can look in the mirror and say "JOB WELL DONE!".
1
33
2,708
From parsing through Prasad tweets to parsing through new Pope tweets (?), seriously does bluesky have anything even remotely close?
4
731
EM PMs: I guess that farm-to-table grocery play in India should trade at 99x rather than 120x in a war scenario 🤔
1
3
742















